title: TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
abstract: Endometrial carcinomas (ECs) are heterogeneous at the genetic level. Although TP53 mutations are highly recurrent in serous endometrial carcinomas (SECs), these are also present in a subset of endometrioid endometrial carcinomas (EECs). Here, we sought to define the frequency, pattern, distribution, and type of TP53 somatic mutations in ECs by performing a reanalysis of the publicly available data from The Cancer Genome Atlas (TCGA). A total of 228 EECs (n=186) and SECs (n=42) from the TCGA data set, for which an integrated genomic characterization was performed, were interrogated for the presence and type of TP53 mutations, and for mutations in genes frequently mutated in ECs. TP53 mutations were found in 15% of EECs and 88% of SECs, and in 91% of copy-number-high and 35% of polymerase (DNA directed), epsilon, catalytic subunit (POLE) integrative genomic subtypes. In addition to differences in prevalence, variations in the type and pattern of TP53 mutations were observed between histologic types and between integrative genomic subtypes. TP53 hotspot mutations were significantly more frequently found in SECs (46%) than in EECs (15%). TP53-mutant EECs significantly more frequently harbored a co-occurring PTEN mutation than TP53-mutant SECs. Finally, a subset of TP53-mutant ECs (22%) was found to harbor frameshift or nonsense mutations. Given that nonsense and frameshift TP53 mutations result in distinct p53 immunohistochemical results that require careful interpretation, and that EECs and SECs display different patterns, types, and distributions of TP53 mutations, the use of the TP53/p53 status alone for the differential diagnosis of EECs and SECs may not be sufficient.
authors.affiliation: Department of Pathology (A.M.S., L.G.M., M.R.D.F., S.P., C.K.Y.N., Y.R.H., J.S.R.-F., R.A.S., B.W.) Human Oncology and Pathogenesis Program (J.S.R.-F.), Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Schultheis
authors.forename: Luciano G
authors.initials: LG
authors.lastname: Martelotto
authors.forename: Maria R
authors.initials: MR
authors.lastname: De Filippo
authors.forename: Salvatore
authors.initials: S
authors.lastname: Piscuglio
authors.forename: Charlotte K Y
authors.initials: CK
authors.lastname: Ng
authors.forename: Yaser R
authors.initials: YR
authors.lastname: Hussein
authors.forename: Jorge S
authors.initials: JS
authors.lastname: Reis-Filho
authors.forename: Robert A
authors.initials: RA
authors.lastname: Soslow
authors.forename: Britta
authors.initials: B
authors.lastname: Weigelt
mesh_terms: D018269:Carcinoma, Endometrioid / Q000175:diagnosis / Q000235:genetics*; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis / Q000235:genetics*; D004252:DNA Mutational Analysis; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000235:genetics*; D004717:Endometrium / Q000473:pathology; D005260:Female; D016678:Genome / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D009154:Mutation; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human